Oncolytics Biotech Inc. (Nasdaq: ONCY) has completed patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE